AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference

November 25, 2019 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 25, 2019--

Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference at 11:30 am ET on Thursday, December 5, 2019, in New York City.

A live webcast of the presentation can be accessed under “ Event Calendar ” in the Investors & Media section of the Company’s website. An archived webcast recording will be available on the Synlogic website for approximately 30 days after the event.

About Synlogic
Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s lead program, SYNB1618, targets PKU. When delivered orally, Synthetic Biotic medicines can act from the gut to compensate for the dysfunctional metabolic pathway and have a systemic effect, with the potential to significantly improve symptoms of disease for affected patients. In addition, the Company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including inflammatory and immune disorders, and cancer. Synlogic’s first immuno-oncology program, SYNB1891, is in clinical development for the treatment of solid tumors and lymphoma. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191125005743/en/

CONTACT: MEDIA CONTACT:

Caroline Rufo, Ph.D.

MacDougall

Phone: 781-235-3060

Email:crufo@macbiocom.comINVESTOR CONTACT:

Elizabeth Wolffe, Ph.D.

Synlogic, Inc.

Phone: 617-207-5509

Email:liz@synlogictx.com

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK MASSACHUSETTS

INDUSTRY KEYWORD: PACKAGING ONCOLOGY HEALTH MANUFACTURING CLINICAL TRIALS BIOTECHNOLOGY

SOURCE: Synlogic

Copyright Business Wire 2019.

PUB: 11/25/2019 04:02 PM/DISC: 11/25/2019 04:02 PM

http://www.businesswire.com/news/home/20191125005743/en